Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide) and Bradykinin, published as a randomized controlled trial.

Angiotensin-converting enzyme and neutral endopeptidase (EC 3.4.24.11; neprilysin) are metallopeptidases present on the endothelium that metabolize bradykinin.

Inhibitors of angiotensin-converting enzyme potentiate bradykinin-mediated vasodilatation and endothelial tissue plasminogen activator release.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.

Each person switched between ANP (Atrial Natriuretic Peptide) and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Angiotensin-Converting Enzyme Inhibitors, Atrial Natriuretic Factor, Bradykinin, Drug Interactions, Heart Failure, Neprilysin and Nitroprusside.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) and Bradykinin.

The publication is from 2004 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page and the Bradykinin compound page, all human trials.